U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06843187) titled 'Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)' on Jan. 21.
Brief Summary: The goal of this clinical trial is to learn if Lemborexant works to treat residual insomnia in adults with depression that is being treated. It will also learn about how practical, tolerable, and effective Lemborexant is. The main questions it aims to answer are:
* Does Lemborexant help participants improve sleep and reduce insomnia symptoms?
* How practical is it to use Lemborexant (how many participants join, drop out, and follow the study rules)? How do participants feel about using it (based on surveys and intervie...